Mepolizumab Reduced COPD Exacerbations in Clinical Trials
For people with chronic obstructive pulmonary disease, the drug showed benefits that varied based on smoking status and blood markers.
Updated on Sept. 28, 2026 in Asthma
Live Poll
Should medical treatments be prioritized for patients who maintain high-risk lifestyle habits?
An analysis of pooled trial data found that mepolizumab decreased the rate of moderate to severe chronic obstructive pulmonary disease (COPD) exacerbations for former and current smokers. These findings, published on September 28, 2026, suggest that treatment efficacy may depend on a patient's blood eosinophil count (BEC).
Why it matters
Managing COPD exacerbations is a primary goal of clinical care to maintain lung function and quality of life. This analysis helps define which patient populations might see the greatest benefit from this biologic therapy based on specific inflammatory biomarkers.
This analysis pooled data from the METREX, METREO, and MATINEE randomized clinical trials to assess outcomes in patients with blood eosinophil counts (BEC) of at least 150 or 300 cells/µL. Researchers identified significant exacerbation reductions in former and current smokers, though findings varied by BEC levels.
The players
GSK
A global pharmaceutical company that focuses on respiratory health, immunology, and oncology, and which funded these clinical trials.
The details
Mepolizumab works as a biologic therapy targeting specific inflammatory pathways often elevated in respiratory conditions. By stratifying patient data by smoking status and BEC, the trials aimed to determine how individual immune profiles influence the drug's effectiveness in preventing respiratory flares. The study highlighted that while former smokers saw significant improvements, including fewer hospitalizations, those patterns were less consistent in current smokers.
Timeline
September 28, 2026
Health Landscape
Mepolizumab is now established as the second biologic approved for the treatment of COPD. This analysis sits within a broader research push to personalize respiratory care by using blood markers to predict which patients will respond best to targeted immune therapies.
If you are living with COPD, it is worth discussing these findings with your doctor to determine if testing your blood eosinophil count is appropriate for your care plan. These data highlight that the response to biologic therapy can vary, making a personalized conversation about your history and current status essential.
The takeaway
This analysis underscores that COPD treatment is becoming increasingly personalized based on specific biomarkers like blood eosinophil counts. Always consult your physician to track your exacerbation frequency and discuss whether new biologic options are suitable for your specific clinical profile.
Further reading
For more on the latest research and clinical developments in chronic respiratory conditions, visit our Asthma section.
Source note: This article includes information reported by Hcplive.
Live Poll
Should medical treatments be prioritized for patients who maintain high-risk lifestyle habits?
